Stockreport

Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model [Seeking Alpha]

Zevra Therapeutics, Inc.  (ZVRA) 
PDF Miplyffa's rapid adoption in the ultra-rare NPC market, supported by expanded payer coverage and diagnostic initiatives, underpins ZVRA's strong commercial momentum. [Read more]